Chronic wounds remain a major challenge in modern medicine and represent a significant health care burden. Several treatments have been suggested, but without a full understanding of the exact mechanism by which chronic wound occurs. Numerous studies have shown that mesenchymal stem cells/multipotent mesenchymal stromal cells (MSCs) may have therapeutic potential in healing cutaneous chronic wounds through various mechanisms. So far, a series of hypotheses have been proposed, but a holistic image of them is lacking. This review provides a systematic analysis of recent research in animal models and preclinical or clinic trails to evaluate the potential role of MSCs in chronic cutaneous wound healing. Most important, we highlight how mesenchymal stem cells could potentially revolutionize our approach to treating cutaneous chronic wounds. Special attention should be focused on ongoing research regarding the challenges in using and prospects of MSCs in clinical settings.
BitschMLaursenIEngelAM. Epidemiology of chronic wound patients and relation to serum levels of mannan-binding lectin. Acta Derm Venereol. 2009;89:607-611.
2.
JiangYHuangSFuX. Epidemiology of chronic cutaneous wounds in China. Wound Repair Regen. 2011;19:181-188.
3.
FanWPLRashidMEnochS. Current advances in modern wound healing. Wounds UK. 2010;6:22-36.
4.
SummerEH. Mesenchymal stem cells: a multimodality option for wound healing. Adv Wound Care. 2012;1:153-158.
5.
ChagastellesPCNardiNBCamassolaM. Biology and applications of mesenchymal stem cells. Sci Prog. 2010; 93:113-127.
6.
FathkeCWilsonLHutterJ. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells. 2004;22:812-822.
7.
VojtassakJDanisovicLKubesM. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett. 2006;27(suppl 2):134-137.
BoykoEJAhroniJHStenselVForsbergRCDavignonDRSmithDG. A prospective study of risk factors for diabetic foot ulcer. the Seattle Diabetic Foot Study. Diabetes Care. 1999;22:1036-1042.
10.
MustoeT. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg. 2004;187:65-70.
11.
BremHTomic-CanicM. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117:1219-1222.
BishopA. Role of oxygen in wound healing. J Wound Care. 2008;17:399-402.
14.
RodriguezPGFelixFNWoodleyDTShimEK. The role of oxygen in wound healing: a review of the literature. Dermatol Surg. 2008;34:1159-1169.
15.
EmingSAKriegTDavidsonJM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007;127:514-525.
16.
IshidaYKTTakayasuTIwakuraYMukaidaN. The essential involvement of cross-talk between IFN-g and TGF-b in the skin wound healing process. J Immunol. 2004;172:1848-1855.
17.
FrykbergRG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002;66:1655-1662.
18.
BarrickBCampellEJOwenCA. Leukocyte proteinases in wound healing: roles in physiologic and pathological processes. Wound Repair Regen. 1999;7:410-422.
19.
HardingKGMorrisHLPatelGK. Science, medicine and the future: healing chronic wounds. BMJ. 2002;324:160-163.
DissemondJ. Modern wound dressings for the therapy of chronic wounds. Hautarzt. 2006;57:881-887.
22.
PechterPMGilJValdesJ. Keratin dressings speed epithelialization of deep partial-thickness wounds. Wound Repair Regen. 2012;20:236-242.
23.
TangLSierraJOKellyRKirsnerRSLiJ. Wool-derived keratin stimulates human keratinocyte migration and types IV and VII collagen expression. Exp Dermatol. 2012;21:458-460.
EvansDLandL. Topical negative pressure for treating chronic wounds: a systematic review. Br J Plast Surg. 2001;54:238-242.
26.
BanwellPEMusgraveM. Topical negative pressure therapy: mechanisms and indications. Int Wound J. 2004;1: 95-106.
27.
ShirakawaMIsseroffRR. Topical negative pressure devices: use for enhancement of healing chronic wounds. Arch Dermatol. 2005;141:1449-1453.
28.
ArmstrongDGLaveryLA. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366:1704-1710.
29.
TauroLFRavikrishnanJRao-SatishBSDivakar-ShenoyHShettySRMenezesLT. A comparative study of the efficacy of topical negative pressure moist dressings and conventional moist dressings in chronic wounds. Indian J Plast Surg. 2007;40:133-140.
30.
UbbinkDTWesterbosSJNelsonEAVermeulenH. A systematic review of topical negative pressure therapy for acute and chronic wounds. Br J Surg. 2008;95:685-692.
31.
LondahlMKatzmanPNilssonAHammarlundC. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010;33:998-1003.
32.
Roeckl-WiedmannIBennettMKrankeP. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg. 2005;92:24-32.
33.
CharbordP. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther. 2010;21:1045-1056.
34.
DominiciMLe BlancKMuellerI. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
35.
WuYZhaoRCTredgetEE. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells. 2010;28:905-915.
OswaldJBoxbergerSJorgensenB. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22:377-384.
38.
PaunescuVDeakEHermanD. In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med. 2007;11:502-508.
39.
WuYChenLScottPGTredgetEE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25:2648-2659.
40.
SasakiMAbeRFujitaYAndoSInokumaDShimizuH. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol. 2008;108:2581-2587.
ProckopD. “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther. 2007;82:241-243.
43.
JavazonEHKeswaniSGBadilloAT. Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bone marrow stromal progenitor cells. Wound Repair Regen. 2007;15:350-359.
44.
SemedoPBurgos-SilvaMDonizetti-OliveiraC. How do mesenchymal stem cells repair?Stem Cells. 2010;4:83-104.
45.
GalianoRDTepperOMPeloCR. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164:1935-1947.
46.
ZentilinLTafuroSZacchignaS. Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood. 2006;107:3546-3554.
47.
Chao-FeiLYanL. Progress of research on mechanisms of vascular maturation. Chin J Inj Repair Wound Healing. 2011;6:279-284.
48.
MurakamiMNguyenLTZhuangZW. The FGF system has a key role in regulating vascular integrity. J Clin Invest. 2008;118:3355-3366.
49.
Tu-LaiYYeh-TingHHsin-YangL. Enhancement of wound healing by human multipotent stromal cell conditioned medium: the paracrine factors and p38 MAPK activation. Cell Transplant. 2011;20:693-706.
50.
KamihataHMatsubaraHNishiueT. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001;104:1046-1052.
51.
CaplanAI. What’s in a name?Tissue Eng Part A. 2010;16:2415-2417.
52.
CutlerAJLimbaniVGirdlestoneJNavarreteCV. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol. 2010;185:6617-6623.
53.
DjouadFCharbonnierL-MBouffiC. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25:2025-2032.
54.
NemethKLeelahavanichkulAYuenPST. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin- 10 production. Nat Med. 2008;15:42-49.
55.
SelmaniZNajiAZidiI. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008;26:212-222.
56.
TraggiaiEVolpiSSchenaF. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells. 2008;26:562-569.
57.
ZhangQZSuWRShiSH. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells. 2010;28:1856-1868.
58.
TuZLiQBuHLinF. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 2010;19:1803-1809.
59.
ParkM-JShinJ-SKimY-H. Murine mesenchymal stem cells suppress T lymphocyte activation through IL-2 receptor α(CD25) cleavage by producing matrix metalloproteinases. Stem Cell Rev. 2011;7:381-393.
60.
UccelliAMorettaLPistoiaV. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-736.
61.
MorandiFRaffaghelloLBianchiG. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008;26:1275-1287.
KramperaMCosmiLAngeliR. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-398.
64.
RyanJMBarryFMurphyJMMahonBP. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353-363.
65.
SpaggiariGMCapobiancoAAbdelrazikHBecchettiFMingariMCMorettaL. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111:1327-1333.
66.
RenGZhangLZhaoX. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141-150.
67.
KitaoriTItoHSchwarzEM. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009;60:813-823.
68.
VillaronEAlmeidaJLopez-HolgadoN. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation. Haematologica. 2004;89:1421-1427.
69.
CeradiniDJKulkarniARCallaghanMJ. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858-864.
70.
HuiLHongYJingjingZYuanHQiCNongZ. HGF suppresses high glucose-mediated oxidative stress in mesangial cells by activation of PKG and inhibition of PKA. Free Radic Biol Med. 2010;49:467-473.
71.
KortesidisAZannettinoAIsenmannSShiSLapidotTGronthosS. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood. 2005;105:3793-3801.
72.
LiLJiangJ. Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms. Front Med. 2011;5:33-39.
73.
KimW-SParkB-SSungJ-H. The wound-healing and antioxidant effects of adipose-derived stem cells. Expert Opin Biol Ther. 2009;9:879-887.
74.
KimWSParkBSKimHK. Evidence supporting antioxidant action of adipose-derived stem cells: protection of human dermal fibroblasts from oxidative stress. J Dermatol Sci. 2008;49:133-142.
75.
KempKGordonDWraithDC. Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells. Neuropathol Appl Neurobiol. 2011;37:166-178.
76.
ProckopDJGregoryCASpeesJL. One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci U S A. 2003;100:11917-11923.
77.
GangZXiao-BingFTong-ZhuS. Genes expression profie in the co-culture of human bone marrow mesenchymal stem cells with sweat glands cells and the implication. Chin J Exp Surg. 2007;24:1186-1188.
78.
InalJMAnsa-AddoEAStrattonD. Microvesicles in health and disease. Arch Immunol Ther Exp (Warsz). 2012;60:107-121.
79.
HugelBMartinezMCKunzelmannCFreyssinetJM. Membrane microparticles: two sides of the coin. Physiology (Bethesda). 2005;20:22-27.
80.
TettaCBrunoSFonsatoVDeregibusMCCamussiG. The role of microvesicles in tissue repair. Organogenesis. 2011;7:105-115.
81.
FalangaVIwamotoSChartierM. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007;13:1299-1312.
82.
PiaoWWangHInoueMHasegawaMHamadaHHuangJ. Transplantation of Sendai viral angiopoietin-1-modified mesenchymal stem cells for ischemic limb disease. Angiogenesis. 2010;13:203-210.
83.
GauglitzGGJeschkeMG. Combined gene and stem cell therapy for cutaneous wound healing. Mol Pharm. 2011;8:1471-1479.
